Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:QNTM NASDAQ:RAPT NASDAQ:TIL NASDAQ:TRDA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeQNTMQuantum Biopharma$17.23+7.6%$20.28$2.70▼$38.25$61.13M0.77133,318 shs149,001 shsRAPTRapt Therapeutics$16.22+3.3%$11.28$5.67▼$26.56$259.65M-0.174,810 shs340,100 shsTILInstil Bio$24.10+1.3%$26.84$10.80▼$92.00$160.67M2.16131,654 shs207,470 shsTRDAEntrada Therapeutics$5.28-0.9%$5.87$4.93▼$21.79$202.74M-0.13221,948 shs244,295 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceQNTMQuantum Biopharma+7.55%+22.55%-25.89%-12.49%+341.79%RAPTRapt Therapeutics+3.31%+25.44%+53.02%+94.95%+5.05%TILInstil Bio+1.26%-23.49%-10.64%-29.59%-18.72%TRDAEntrada Therapeutics-0.94%-0.19%-0.75%-30.43%-64.47%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeQNTMQuantum Biopharma$17.23+7.6%$20.28$2.70▼$38.25$61.13M0.77133,318 shs149,001 shsRAPTRapt Therapeutics$16.22+3.3%$11.28$5.67▼$26.56$259.65M-0.174,810 shs340,100 shsTILInstil Bio$24.10+1.3%$26.84$10.80▼$92.00$160.67M2.16131,654 shs207,470 shsTRDAEntrada Therapeutics$5.28-0.9%$5.87$4.93▼$21.79$202.74M-0.13221,948 shs244,295 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceQNTMQuantum Biopharma+7.55%+22.55%-25.89%-12.49%+341.79%RAPTRapt Therapeutics+3.31%+25.44%+53.02%+94.95%+5.05%TILInstil Bio+1.26%-23.49%-10.64%-29.59%-18.72%TRDAEntrada Therapeutics-0.94%-0.19%-0.75%-30.43%-64.47%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceQNTMQuantum Biopharma 0.00N/AN/AN/ARAPTRapt Therapeutics 2.50Moderate Buy$21.5732.99% UpsideTILInstil Bio 3.00Buy$88.50267.22% UpsideTRDAEntrada Therapeutics 3.00Buy$25.67386.11% UpsideCurrent Analyst Ratings BreakdownLatest QNTM, RAPT, TIL, and TRDA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/11/2025TILInstil BioHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$125.00 ➝ $125.008/27/2025TILInstil BioHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$125.00 ➝ $125.008/22/2025RAPTRapt TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold8/15/2025TILInstil BioHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$125.00 ➝ $125.008/12/2025RAPTRapt TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetNeutral$8.00 ➝ $9.008/8/2025RAPTRapt TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$51.00 ➝ $38.008/8/2025TRDAEntrada TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold7/30/2025RAPTRapt TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeUnderweight ➝ Neutral$14.007/22/2025RAPTRapt TherapeuticsLifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy$31.007/10/2025RAPTRapt TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$27.006/18/2025QNTMQuantum BiopharmaSingular ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeModerate Buy(Data available from 9/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookQNTMQuantum BiopharmaN/AN/AN/AN/A$4.54 per shareN/ARAPTRapt TherapeuticsN/AN/AN/AN/A$11.51 per shareN/ATILInstil BioN/AN/AN/AN/A$25.96 per shareN/ATRDAEntrada Therapeutics$210.78M0.95$1.57 per share3.36$11.46 per share0.46Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateQNTMQuantum Biopharma-$14.20M-$14.02N/AN/AN/AN/A-270.22%-131.87%11/10/2025 (Estimated)RAPTRapt Therapeutics-$129.87M-$14.17N/AN/AN/AN/A-67.92%-59.59%11/11/2025 (Estimated)TILInstil Bio-$74.14M-$12.92N/AN/AN/AN/A-54.32%-33.65%11/12/2025 (Estimated)TRDAEntrada Therapeutics$65.63M-$1.78N/AN/AN/A-92.30%-17.81%-14.55%11/4/2025 (Estimated)Latest QNTM, RAPT, TIL, and TRDA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025TILInstil Bio-$1.72-$3.24-$1.52-$3.24N/AN/A8/7/2025Q2 2025RAPTRapt Therapeutics-$0.61-$0.65-$0.04-$0.65N/AN/A8/6/2025Q2 2025QNTMQuantum Biopharma-$0.17-$3.23-$3.06-$3.23$2.89 millionN/A8/6/2025Q2 2025TRDAEntrada Therapeutics-$0.86-$1.04-$0.18-$1.04$8.17 million$1.98 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthQNTMQuantum BiopharmaN/AN/AN/AN/AN/ARAPTRapt TherapeuticsN/AN/AN/AN/AN/ATILInstil BioN/AN/AN/AN/AN/ATRDAEntrada TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioQNTMQuantum BiopharmaN/A0.780.77RAPTRapt TherapeuticsN/A13.2513.25TILInstil Bio0.6414.9714.97TRDAEntrada TherapeuticsN/A18.6418.64Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipQNTMQuantum Biopharma1.24%RAPTRapt Therapeutics99.09%TILInstil Bio60.56%TRDAEntrada Therapeutics86.39%Insider OwnershipCompanyInsider OwnershipQNTMQuantum Biopharma8.53%RAPTRapt Therapeutics2.36%TILInstil Bio47.20%TRDAEntrada Therapeutics8.11%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableQNTMQuantum BiopharmaN/A3.82 million3.49 millionN/ARAPTRapt Therapeutics8016.54 million16.15 millionOptionableTILInstil Bio4106.75 million3.57 millionNo DataTRDAEntrada Therapeutics11038.04 million34.95 millionOptionableQNTM, RAPT, TIL, and TRDA HeadlinesRecent News About These CompaniesEntrada Therapeutics, Inc. (NASDAQ:TRDA) Given Consensus Rating of "Buy" by BrokeragesSeptember 11 at 4:39 AM | marketbeat.comNuveen LLC Purchases Shares of 67,016 Entrada Therapeutics, Inc. $TRDASeptember 6, 2025 | marketbeat.comEntrada Therapeutics Announces Recipients of Third Annual DREAMS Grant ProgramSeptember 5, 2025 | globenewswire.comEntrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 2, 2025 | globenewswire.comMerck & Co. Inc. Takes Position in Entrada Therapeutics, Inc. $TRDAAugust 26, 2025 | marketbeat.comConnor Clark & Lunn Investment Management Ltd. Sells 74,068 Shares of Entrada Therapeutics, Inc. $TRDAAugust 23, 2025 | marketbeat.comEntrada Therapeutics, Inc. (NASDAQ:TRDA) Receives Average Rating of "Buy" from BrokeragesAugust 17, 2025 | marketbeat.comEntrada (TRDA) Q2 Revenue Drops 98%August 11, 2025 | theglobeandmail.comEntrada Therapeutics, Inc. (NASDAQ:TRDA) Analysts Are Cutting Their Estimates: Here's What You Need To KnowAugust 9, 2025 | finance.yahoo.comEntrada Therapeutics, Inc. (TRDA) Reports Q2 Loss, Lags Revenue EstimatesAugust 6, 2025 | zacks.comEntrada Therapeutics Reports Second Quarter 2025 Financial ResultsAugust 6, 2025 | globenewswire.comEntrada Therapeutics (TRDA) Soars 5.6%: Is Further Upside Left in the Stock?July 31, 2025 | zacks.com5am Ventures v sells Entrada Therapeutics (TRDA) stock for $202kJuly 13, 2025 | investing.comEntrada therapeutics (TRDA) director Parmar sells $202k in stockJuly 13, 2025 | investing.comVentures V. L.P. 5Am Sells 6,935 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) StockJuly 12, 2025 | insidertrades.comEntrada Therapeutics (TRDA) 10% owners sell $866k in stockJuly 3, 2025 | investing.comEntrada Therapeutics, Inc. (NASDAQ:TRDA) Major Shareholder Ventures V. L.P. 5Am Sells 6,422 SharesJuly 2, 2025 | insidertrades.comEntrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of DirectorsJune 3, 2025 | globenewswire.comEntrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 2, 2025 | globenewswire.comEntrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients ...May 29, 2025 | morningstar.comMEntrada Therapeutics to start DMD trial in Q3 2025May 29, 2025 | investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesCan AI Defense Contracts Push Palantir Shares Higher?By Chris Markoch | August 19, 2025Jackson Hole 2025: Fed’s Signal Could Shift Stocks FastBy Chris Markoch | August 20, 2025Big Rallies Brewing? 3 Analyst Favorites to Watch CloselyBy Nathan Reiff | August 18, 2025Lowe’s Builds Value for Investors: Still a Good Buy in 2025By Thomas Hughes | August 20, 2025Is Viking’s Growth Still Worth the Premium?By Chris Markoch | August 20, 2025QNTM, RAPT, TIL, and TRDA Company DescriptionsQuantum Biopharma NASDAQ:QNTM$17.23 +1.21 (+7.55%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$17.21 -0.02 (-0.14%) As of 09/12/2025 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company's three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property. The company was founded by Thomas Fairfull, Zeeshan Saeed and Anthony J. Durkacz on October 20, 1994 and is headquartered in Toronto, Canada.Rapt Therapeutics NASDAQ:RAPT$16.22 +0.52 (+3.31%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$16.63 +0.41 (+2.53%) As of 09/12/2025 06:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. RAPT Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb CompanyInstil Bio NASDAQ:TIL$24.10 +0.30 (+1.26%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$23.93 -0.17 (-0.71%) As of 09/12/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Instil Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies. The company develops cell therapy of tumor infiltrating lymphocyte (TIL) for the treatment of cancer. It is developing early-stage pipeline of CoStAR-TIL and other novel TIL technologies. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas.Entrada Therapeutics NASDAQ:TRDA$5.28 -0.05 (-0.94%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$5.36 +0.08 (+1.42%) As of 09/12/2025 04:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45 and ENTR-601-50, which are in preclinical trail for the treatment of Duchenne muscular dystrophy; and ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/08 - 09/12 Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Tesla's U.S. Market Is At An 8-Year Low... How Bad Could It Get? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
